https://www.selleckchem.com/pr....oducts/PD-0325901.ht
The GLP-1 agonists can be used in people with CKD if SGLT2i are not tolerated. Current evidence suggests SGLT2i as preferred agents among people with T2D and HF, and for those with T2D and ASCVD. SGLT2i and GLP-1RA also lower CV outcomes in those with diabetes and ASCVD, and the treatment choice should depend on the patient profile. Current evidence suggests SGLT2i as preferred agents among people with T2D and HF, and for those with T2D and ASCVD. SGLT2i and GLP-1RA also lower CV outcomes in those with diabetes and ASCVD, and the tre
Me gusta
Comentario
Compartir
